A single-arm pilot study investigating the combination of PD1/PD-L1 blockade with CTLA-4 inhibition reported an objective response rate (ORR) of 43% in patients with metastatic TNBC, whereas no responses were observed in patients with HR+ breast cancer (121). The gene discussed is CD274; the disease is breast cancer.